Becherel Pierre André, Reguiai Ziad, Fougerousse Anne Claire, Perrot Jean Luc, Begon Edouard, Thomas-Beaulieu Domitille, Mery-Bossard Laure, Pourchot Diane, Boulard Claire, Fite Charlotte, Beaziz Jessica, Zaraa Inès, Lons-Danic Dominique, Badaoui Antoine, Parier Josiane, Chaby Guillaume, Estève Eric, Liegeon Anne-Laure, Patchinsky Alexandra, Muller Philippe, Lepelley-Dupont Charlotte, Poreaux Claire, Jacobzone-Lévêque Caroline, Chassain Kevin, Mohty Rima, Perrussel Marc, Garcia Charline, Girard Céline, Dillies Anne Sophie, Amy de la Breteque Maud, Quiles-Tsimaratos Nathalie, Denis Daphné, Maccari François
Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France.
Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
Dermatology. 2024;240(5-6):702-712. doi: 10.1159/000540250. Epub 2024 Jul 17.
Chronic inflammatory dermatoses (CIDs) can significantly affect patients' lives. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) cohort was initiated to quantify the impact and disease evolution of four CID over 4 years' follow-up; at least 1,000 patients per CID are planned to be enrolled. The objective of this study was to present baseline characteristics of patients included in the OMCCI cohort between December 2020 and September 2022.
This French, prospective, multicenter registry included adult patients treated in daily practice for moderate-to-severe psoriasis (PS), atopic dermatitis (AD), hidradenitis suppurativa (HS), or chronic urticaria (CU) starting or modifying a systemic treatment. At the inclusion visit and then every 6 months during 4 years, patient-reported outcomes and data on these diseases and their treatments are recorded.
A total of 2,058 patients from 24 centers were included: 1,137 PS, 413 AD, 301 HS, and 207 CU. Of these, 1,950 patients started or changed systemic treatment, and 108 reduced the dose of existing systemic treatment. Disease impact was qualified as debilitating by 80.1% (PS), 90.5% (AD), 90.5% (HS), and 89.4% (CU), affecting daily, family, and professional life. According to the SF-12 Survey, the impact of all four diseases was borderline pathological for physical health and severe for mental health. At inclusion, 20.4% of patients were receiving a conventional systemic or biologic treatment. After the first visit, this percentage raised to 83.3%. During the 6 months preceding study inclusion, 17.7% (PS), 27.9% (AD), 43.1% (HS), and 43.6% (CU) of patients missed work due to their illness, and 26.3% of patients with HS had been admitted to hospital (vs. 8.1%, 5.8%, and 13% of patients with PS, AD, or CU, respectively).
These CIDs (especially HS) had a major impact on all aspects of patients' quality of life. The low baseline use of systemic drugs and the high burden of these CIDs suggest that these agents are underused. Long-term and dynamic evaluation of the changes brought by the initiation or optimization of these treatments on the evolution of patients' lives will be studied prospectively during the 4-year follow-up of the OMCCI.
慢性炎症性皮肤病（CIDs）会对患者生活产生重大影响。慢性炎症性皮肤病观察站（OMCCI）队列研究旨在通过4年随访量化四种CIDs的影响及疾病演变；计划每种CIDs至少纳入1000名患者。本研究的目的是呈现2020年12月至2022年9月纳入OMCCI队列患者的基线特征。
这项法国前瞻性多中心登记研究纳入了在日常临床中接受中度至重度银屑病（PS）、特应性皮炎（AD）、化脓性汗腺炎（HS）或慢性荨麻疹（CU）系统治疗起始或调整治疗的成年患者。在纳入访视时以及随后4年中每6个月，记录患者报告的结局以及这些疾病及其治疗的数据。
共纳入来自24个中心的2058例患者：1137例PS、413例AD、301例HS和207例CU。其中，1950例患者起始或更改了系统治疗，108例患者减少了现有系统治疗的剂量。疾病影响被判定为使生活衰弱的比例分别为80.1%（PS）、90.5%（AD）、90.5%（HS）和89.4%（CU），影响到日常、家庭和职业生活。根据SF - 12调查，所有四种疾病对身体健康的影响处于临界病态，对心理健康的影响严重。纳入时，20.4%的患者正在接受传统系统治疗或生物治疗。首次访视后，这一比例升至83.3%。在研究纳入前的6个月内，17.7%（PS）、27.9%（AD）、43.1%（HS）和43.6%（CU）的患者因病缺勤，26.3%的HS患者曾住院治疗（而PS、AD或CU患者的这一比例分别为8.1%、5.8%和13%）。
这些CIDs（尤其是HS）对患者生活的各个方面都有重大影响。系统药物的低基线使用以及这些CIDs的高负担表明这些药物未得到充分利用。在OMCCI的4年随访中将前瞻性研究这些治疗的起始或优化给患者生活演变带来的变化的长期动态评估。
